Cross-linked Hyaluronic Dermal Filler Evryàl Medium
Evryàl Cross-linked Medium Hyaluronic Dermal Filler in pre-filled syringe 1ml.
FOR MEDICAL USE ONLY
Info about products and orders Tel: 0039 051 0395855 Whatsapp: 0039 342 7089807
EU VAT number owner? Sign up as a company and you will not pay Italian 22% VAT
Are you a reseller? Contact us for a special price list email: email@example.com
FOR MEDICAL USE ONLY
Cross-linked Hyaluronic Dermal filler Evryàl Medium 20 mg/ml
A NEW GENERATION OF CROSS-LINKED HYALURONIC ACID FILLERS FOR THE TREATMENT OF SKIN BLEMISHES
EVRYÀL is a sterile, highly tolerated, viscoelastic iller made with cross-linked hyaluronic acid, ideal for subcutaneous applications. EVRYÀL helps increase the volume of the dermo-epidermal tissue thanks to the natural ability of hydrophilic hyaluronic acid molecules to attract a moderate amount of water molecules and bond with them. This allows the integration of the intercellular matrix, whilst illing intradermal spaces and making the tissues irmer.The cross-linked hyaluronic acid contained in the product makes this illing efect longer lasting and more stable. In fact, unlike linear hyaluronic acid, the skin slowly absorbs EVRYÀL in 6 to 8months, looking more natural for longer. In addition to safety, BDDE – the cross-linking agent – provides efective results, thereby meeting market requirements. EVRYÀL is a CE 0373 injectable, apyrogenic, resorbable medical device made with cross-linked hyaluronic acid created from non-animal sourced bacterial bio-fermentation.
It is a colourless monophasic gel contained in a disposable pre-illed, ergonomic syringe with a Luer Lock adapter. The syringe is equipped with a plastic support that makes it easy to handle. Its accurate graduation allows you to control and read the volume of injected product. Electronic veriications carried out throughout the entire iller production and packaging process, based on the use of state of the art technology, ensure quality, purity, and safety. These production standards, together with the extremely low concentration of nucleic acids and protein, and the bacterial endoxin rate < 0.5 EU/ml (much lower than the limit established by the European Pharmacopoeia for injectable products) minimise any hypersensitivity reaction.
A preclinical trial conducted by ten specialists (dermatologists, plastic surgeons, and cosmetic physicians) on 145 patients (women with a mean age of 50 years) over the course of one year has shown an excellent durability of the product. The graph n. 1 shows the duration of the treatment with the three dosages. The satisfaction questionnaires illed out by the specialists involved in the study showed an average satisfaction index (ASI) of 8/10 for both patients and physicians. The parameters taken into the consideration in the questionnaire were the malleability and tolerability of the product, its immediate efect, pain during the treatment (which resulted to be non-existent or tolerable), and the absence of edema (graph n. 2).
Three diferent dosages allow for the treatment of any area of the face, reducing any type of wrinkle (fine to deep), reshaping the face contour and lips, and hydrating the skin in depth. The result is very natural and immediately visible. EVRYÀL has an immediate lifting efect, thanks to its intrinsic viscoelastic and hydrophilic properties, which help recreate the desired volume.
EVRYÀL is injected subcutaneously to eliminate or at least reduce both supericial and deep wrinkles and increase soft tissue volume (lips, cheekbones, cheeks) for face countouring or reconstructive procedures (depressed scars, acne or chicken pox outcomes, facial asymmetry and atrophy, non-surgical rhinoplasty). his allows for safe, long-lasting results, considering that resorption occurs gradually over 6 to 8 months from treatment. The treatment can be safely repeated once the illing efects are signiicantly attenuated. Ease of use and intrinsic safety facilitate the physician performing the treatment. After thorough cleansing and disinfection of the skin, a few microinjections in the areas to be treated is all it takes. The treatment is well tolerated and not painful.
Treatment of periocular wrinkles. We recommend the linear retrograde injection technique, which should trace the path of the wrinkle with extreme precision. Avoid hypercorrections. This technique requires stretching the skin between the ingers of the hand not holding the syringe, carefully avoiding surface capillaries. After the injection, it is important to massage the treated area to spread the product subcutaneously.
Indicated for the treatment of perioral wrinkles and for lip and eyebrow contouring. The product is injected into the superficial dermis, avoiding hypercorrections. If necessary, the physician can perform corrections with both the serial puncture and linear retrograde techniques, according to her dexterity. We recommend massaging the treated parts.
Treatment of medium to deep face wrinkles, volume augmentation of cheekbones, chin, nose bridge, and lips.
The linear retrograde technique should be chosen over the serial puncture technique. We recommend injecting the product into the deep dermal layer.
|CONCENTRATION||15 mg/ml||20 mg/ml||25 mg/ml|
|PH||6.00 – 7.50||6.00 – 7.50||6.00 – 7.50|
|INITIAL HYALURONIC ACID
|2,400-4,000 kDa||2,400-4,000 kDa||2,400-4,000 kDa|
|TOTAL ENDOTOXINS||< 0.5 EU/ml||< 0.5 EU/ml||< 0.5 EU/ml|
|Treatment of deep
|INJECTION AREA||Medium-deep dermal layer,
|Possibly the deepest
|Deep or supraperiosteal
|ONE BOX CONTAINS||Sterile syringe 1x1 mL||Sterile syringe 1x1 mL||Sterile syringe 1x1 mL|
|DURATION OF RESULTS||6-8 Months||6-8 Months||6-8 Months|
|NEEDLES||2x30G 1/2”||1x27G 1/2” - 1x26G 1/2”||1x27G 1/2” - 1x26G 1/2”|
Evryàl is produced in Italy by Apharm S.r.l.
Evryàl is a medical device CE 0373
You might also like
Face and décolleté post filler gel Platinum Hyaluronic Forte regenerating hyaluronic. It contains hyaluronic acid with an high concentration. Produced by Officina Cosmetologica Milano. Airless 30ml bottle.